Abstract
Background
N-acetylcysteine (NAC), as a precursor of glutathione, may decrease oxidative stress in the body when the body's immunity is disrupted and may play an anti-inflammatory and immune-regulating function to safeguard the body's stability. In clinical practice, the qualities of NAC are also employed to patients with viral hepatitis and sepsis and are now being aggressively stressed in the treatment of coronavirus disease 2019 (COVID-19). NAC supplementation might restore this redox balance and decrease adverse evolution in individuals with COVID-19. to explore if there is a change in patients' symptoms after infection when taking the drug before infection.
Methods
This study was done at the Affiliated Hospital of Jinzhou, Liaoning, China, to explore whether medication may affect symptoms after coronavirus disease 2019 (COVID-19). In this study, 219 patients who were infected with COVID-19 and have been on NAC for a while.They were questioned about their cough and sputum, myalgia, fever, dizziness, exhaustion, and anxiety after infection by telephone.
Results
After stratification, there were no significant changes in age, gender, and comorbidities among the three groups of varied age groups, and the baseline values were equal.Our results found that the relationship between NAC administration and symptoms was significant in patients who had few external interfering factors and were well themselves.
Conclusions
NAC may have a favorable impact on the symptoms of COVID-19. The feedback impact of NAC is more prominent in individuals who have a preponderance of their own health state, lifestyle behaviors, and age.